Strengths of our study include that our finding of an association between high levels of Ang-2 and improved PFS in vanucizumab-treated patients with wild-type KRAS was seen in tumour tissue data and confirmed in plasma data in separate analyses. This evidence concerns the gene KRAS and neoplasm.